The corrected release reads: SELECTA BIOSCIENCES TO ACCELERATE PROGRAM FOR NOVEL DUAL ACTION VACCINE FOR MALARIA Grant from the
Selecta's proprietary SVP technology can be designed to activate the immune system in order to enable dual action vaccines by individually optimizing nanoparticles against multiple antigens and by allowing their combinatorial testing. If successful, a dual action, immune-activating SVP nanoparticle vaccine could offer the potential to protect against malaria by both fighting the parasite during early infection, and simultaneously blocking malaria transmission via infected mosquitoes. The biodegradable nanoparticle also permits targeted delivery and controlled release of immune boosting adjuvants to relevant immune cells, thereby shielding the adjuvants from interactions with other cells that may induce the undesirable side-effects associated with other adjuvants.
Selecta's lead formulation for malaria has been developed by systematically optimizing the immune response to various key parameters, such as adjuvant release rate, antigen and adjuvant load and nanoparticle size. The candidate was designed and selected based upon its demonstrated ability in preclinical rodent studies to outperform benchmarks in terms of antibody levels and protection in a malaria parasite challenge model. Selecta's malaria program will build on efforts that began in 2011 under a
"Working with a global leader in vaccines, such as the
Selecta's immunomodulatory SVPs can induce antigen-specific immune tolerance, enabling them to be applied in a variety of therapeutic areas with large unmet medical need. The company is focused on three key near-term applications: inhibition of immunogenicity for biologic therapies, treatment of allergies, and treatment of autoimmune diseases. Immunogenicity adversely affects the safety and efficacy profile for many biological therapies, and has caused the termination of a number of promising biological therapies in clinical development. Selecta's SVP is a product engine that has the potential to unlock the full therapeutic value of biological therapies.
Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, Selecta is building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases.
Keywords for this news article include: Antigens, Biotechnology, Chemicals, Chemistry, Synthetic Vaccines, Selecta Biosciences.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Steven Sotloff Beheading Video Claimed by Islamic State
- Fantasy Football Gambling Industry Facing Increased Legal Scrutiny
- Apple Planning to Launch Mobile Wallet
- Men Are the Big Winners in the Jobs Recovery
- Challenge to Texas Voter ID Begins
- Durant Spurns Under Armour to Return to Nike
- Ford Is Finding Success With Its 'Unminivan'
- Netflix Unveils New Way to Share Picks
- Auto Industry Going Back to Bad Habits
- Construction Spending Staged Strong Rebound in July